Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer

Cancer

Volumn 119, Issue 11, 2013, Pages 2048-2060

  Zhu, Junya ^a   Sharma, Dhruv B ^a   Chen, Aileen B ^a   Johnson, Bruce E ^b   Weeks, Jane C ^b   Schrag, Deborah ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

first line chemotherapy; non small cell lung cancer; platinum doublet; propensity score analysis; SEER Medicare; survival

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; COMORBIDITY; DRUG EFFICACY; ELDERLY CARE; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; INCOME; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICARE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOCIAL STATUS; TREATMENT OUTCOME; URBAN RURAL DIFFERENCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEER PROGRAM; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 84878112026     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28022     Document Type: Article

References (54)

1. Iannettoni MD,. Staging strategies for lung cancer. JAMA. 2010; 304: 2296-2297.
2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008; 26: 4617-4625.
3. Davidoff AJ, Tang M, Seal B, Edelman MJ,. Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2010; 28: 2191-2197.
4. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999; 91: 66-72.
5. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011; 378: 1079-1088.
6. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK,; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010; 5: 260-274.
7. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA,. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007; 2: 845-853.
8. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13: 1860-1870.
9. Lilenbaum RC, Herndon JE, 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005; 23: 190-196.
10. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002; 346: 92-98.
11. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005; 47: 69-80.
12. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing 3 platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002; 20: 4285-4291.
13. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003; 21: 3016-3024.
14. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210-3218.
15. Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small cell lung cancer. Ann Oncol. 2010; 21: 540-547.
16. Helbekkmo N, Sundstrm SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007; 97: 283-289.
17. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005; 16: 1069-1075.
18. Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer. 2012; 78: 245-252.
19. Zhu J, Sharma D, Gray SW, Chen AB, Weeks JC, Schrag D,. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012; 307: 1593-1601.
20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
21. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of 2 Phase III studies. Oncologist. 2009; 14: 253-263.
22. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432-1440.
23. Treat J, Edelman MJ, Belani CP, et al. A retrospective analysis of outcomes across histological subgroups in a 3-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2010; 70: 340-346.
24. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in 3 phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011; 6: 64-70.
25. National Cancer Institute. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov. Accessed July 1, 2012.
26. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-IV-18.
27. National Cancer Institute. SEER-Medicare: Medicare Claims Files. Available at: http://healthservices.cancer.gov/seermedicare/medicare/claims. html. Accessed July 1, 2012.
28. Greene FL, Page DL, Fleming ID, Balch CM,; American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Handbook. 6th ed. New York: Springer; 2002.
29. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-55-IV-61.
30. Lamont EB, Herndon JE 2nd, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005; 97: 1080-1083.
31. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL,. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002; 40: IV-19-IV-25.
32. Fritz AG, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
33. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
34. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
36. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
37. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D,. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
38. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
39. Rosenbaum PR, Rubin DB,. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984; 79: 516-524.
40. D'Agostino RB Jr, D'Agostino RB Sr,. Estimating treatment effects using observational data. JAMA. 2007; 297: 314-316.
41. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127: 757-763.
42. D'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med. 1998; 17: 2265-2281.
43. Lunceford JK, Davidian M,. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004; 23: 2937-2960.
44. Robins JM, Herna MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11: 550-560.
45. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-857.
46. Jiang J, Liang X, Zhou X, Huang R, Chu Z,. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007; 57: 348-358.
47. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small cell lung cancer. J Clin Oncol. 2008; 26: 468-473.
48. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30: 2055-2062.
49. Groen HJ, Sietsma H, Vincent A, et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011; 29: 4320-4326.
50. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006; 17: 1111-1119.
51. Clements KM, Peltz G, Faries DE, et al. Does type of tumor histology impact survival among patients with stage IIIB/IV non-small cell lung cancer treated with first-line doublet chemotherapy [serial online]? Chemother Res Pract 2010: 524629, 2010.
52. Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA,. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of 3 phase 3 trials. Lung Cancer. 2012; 76: 222-227.
53. West L, Vidwans SJ, Campbell NP, et al. A novel classification of lung cancer into molecular subtypes [serial online]. PLoS One. 2012; 7: e31906.
54. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) [based on November 2011 SEER data submission, posted to the SEER web site, April 2012]. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975-2009- pops09/. Accessed July 1, 2012.